These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 9364979

  • 1. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M, de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C, Princen HM, Kooistra T.
    Thromb Haemost; 1997 Oct; 78(4):1167-72. PubMed ID: 9364979
    [Abstract] [Full Text] [Related]

  • 2. [Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia].
    Okopień B, Cwalina Ł, Haberka M, Kowalski J, Zieliński M, Szwed Z, Kalina Z, Herman ZS.
    Pol Merkur Lekarski; 2002 Dec; 13(78):465-9. PubMed ID: 12666442
    [Abstract] [Full Text] [Related]

  • 3. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
    de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C.
    Thromb Haemost; 1997 Jan; 77(1):75-9. PubMed ID: 9031453
    [Abstract] [Full Text] [Related]

  • 4. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
    Vigna GB, Donega P, Passaro A, Zanca R, Cattin L, Fonda M, Pauciullo P, Marotta G, Fellin R, Gasparrini S, Piliego T.
    Nutr Metab Cardiovasc Dis; 1999 Oct; 9(5):234-43. PubMed ID: 10656170
    [Abstract] [Full Text] [Related]

  • 5. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
    Kockx M, Princen HM, Kooistra T.
    Thromb Haemost; 1998 Dec; 80(6):942-8. PubMed ID: 9869165
    [Abstract] [Full Text] [Related]

  • 6. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M, Paoletti R.
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [Abstract] [Full Text] [Related]

  • 7. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO, Landin K, Johannsson G, Tengborn L, Bengtsson BA.
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [Abstract] [Full Text] [Related]

  • 8. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
    Okopien B, Cwalina L, Lebek M, Kowalski J, Zielinski M, Wisniewska-Wanat M, Kalina Z, Herman ZS.
    Int J Clin Pharmacol Ther; 2001 Dec; 39(12):551-7. PubMed ID: 11770837
    [Abstract] [Full Text] [Related]

  • 9. Inhibition by fibrates of plasminogen activator inhibitor type-1 expression in human adipocytes and preadipocytes.
    Zirlik A, Ernst S, Leugers A, Willecke F, Sobel BE, Bode C, Nordt TK.
    Thromb Haemost; 2009 Jun; 101(6):1060-9. PubMed ID: 19492148
    [Abstract] [Full Text] [Related]

  • 10. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy.
    Hamsten A, Syvänne M, Silveira A, Luong LA, Nieminen MS, Humphries S, Frick MH, Taskinen MR.
    Thromb Haemost; 2000 Mar; 83(3):397-403. PubMed ID: 10744143
    [Abstract] [Full Text] [Related]

  • 11. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
    Lahlou-Laforet K, Alhenc-Gelas M, Pornin M, Bydlowski S, Seigneur E, Benetos A, Kierzin JM, Scarabin PY, Ducimetiere P, Aiach M, Guize L, Consoli SM.
    Am J Cardiol; 2006 May 01; 97(9):1287-91. PubMed ID: 16635597
    [Abstract] [Full Text] [Related]

  • 12. [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
    Espinosa RA, Rodríguez-Roa E, Nagy E, Mijares ME, Rodríguez-Larralde A, Gil A, Lundberg U, Carvajal Z, Castillo L, Arocha-Piñango CL.
    Invest Clin; 2006 Mar 01; 47(1):35-48. PubMed ID: 16562643
    [Abstract] [Full Text] [Related]

  • 13. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
    Kvasnicka J, Skrha J, Perusicová J, Maslowská H, Pochopová L.
    Cas Lek Cesk; 1996 Mar 20; 135(6):174-7. PubMed ID: 8681360
    [Abstract] [Full Text] [Related]

  • 14. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN.
    Atherosclerosis; 1998 May 20; 138(1):217-25. PubMed ID: 9678787
    [Abstract] [Full Text] [Related]

  • 15. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
    O'Neal DN, O'Brien RC, Timmins KL, Grieve GD, Lau KP, Nicholson GC, Kotowicz MA, Best JD.
    Diabet Med; 1998 Oct 20; 15(10):870-7. PubMed ID: 9796889
    [Abstract] [Full Text] [Related]

  • 16. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
    Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A.
    Thromb Haemost; 1993 Aug 02; 70(2):241-3. PubMed ID: 8236126
    [Abstract] [Full Text] [Related]

  • 17. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C.
    Clin Endocrinol (Oxf); 2006 Mar 02; 64(3):323-9. PubMed ID: 16487444
    [Abstract] [Full Text] [Related]

  • 18. Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men.
    Johansson JO, Egberg N, Asplund-Carlson A, Carlson LA.
    J Cardiovasc Risk; 1997 Jun 02; 4(3):165-71. PubMed ID: 9475670
    [Abstract] [Full Text] [Related]

  • 19. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
    Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H, Takai S.
    Clin Cancer Res; 1998 Jan 02; 4(1):177-82. PubMed ID: 9516968
    [Abstract] [Full Text] [Related]

  • 20. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
    Balogh Z, Seres I, Harangi M, Kovács P, Kakuk G, Paragh G.
    Diabetes Metab; 2001 Nov 02; 27(5 Pt 1):604-10. PubMed ID: 11694861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.